New treatment options for overactive bladder.
Oehlke
Kelley J
KJ
D001572:Benzofurans / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D018727:Muscarinic Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D011759:Pyrrolidines / Q000008:administration & dosage / Q000627:therapeutic use; D011812:Quinuclidines / Q000008:administration & dosage / Q000627:therapeutic use; D000069464:Solifenacin Succinate; D044005:Tetrahydroisoquinolines / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome; D014549:Urinary Incontinence / Q000188:drug therapy* / Q000378:metabolism
D001572:Benzofurans; D018727:Muscarinic Antagonists; D011759:Pyrrolidines; D011812:Quinuclidines; D044005:Tetrahydroisoquinolines; C101207:darifenacin; D000069464:Solifenacin Succinate